header logo image


Page 14«..10..13141516..2030..»

Archive for the ‘Genetic Engineering’ Category

What does science tell us about Adam and Eve? – Washington University in St. Louis Newsroom

Wednesday, June 17th, 2020

This piece is excerpted from a longer article alum T. Wyatt Reynolds, AB 17, wrote for Mere Orthodoxy.

An atheist, a Christian, and a Jew start talking about science and faith. This might seem like it is either the lead up to a joke or the beginning of a fight. Instead, it was the setting of a meeting convened by S. Joshua Swamidass, MD, associate professor of Pathology & Immunology in the School of Medicine and of Biomedical Engineering in the McKelvey School of Engineering. This meeting gathered scientists and theologians of nearly every stripe to discuss his new book, The Genealogical Adam and Eve (Intervarsity Press). Its argument: that there is no intrinsic contradiction between conventional evolutionary theory and belief in Adam and Eve as a couple specially created six thousand years ago.

The book offers an invitation to skeptics on all sides of the issue to consider either a world where evolution could be true, or a world where Adam and Eve could be real.

Most scientific research to date has focused on whether Adam and Eve could have passed on genetic material to everyone living; however, this doesnt seem to be the type of ancestry the Bible is concerned with. Instead, the Bible is quite concerned with genealogy; extended genealogies fill eleven chapters of Genesis. Who begat whom, and what is the history of their line? This is an entirely different question, and as it turns out, one that can be explored with population genetics. While all genetic ancestors are genealogical ancestors, the inverse is not necessarily true.

So, what does this mean for Adam and Eve? Well, in 2004, a computer simulation of life on Earth was created to test and see when the most recent common ancestor for all humans was. The researchers put higher barriers than historically existed to stack the odds against there being a common ancestor in the recent past. Despite this, the results, published in Nature, found common ancestors only two or three thousand years ago.

Most of these common ancestors are genetic ghosts, meaning that though they are your ancestor, you have inherited no DNA from them. This means that universal ancestors are both surprisingly recent and surprisingly hidden. Swamidass also includes engrossing theological, historical, and philosophical tidbits sprinkled in amidst the science. The book and author are truly making room for many voices at the table of discussion.

The cover art plays a critical role here as it marries DNA strands with a reflective gold foil reminiscent of Makoto Fujimuras paintings. The cover brings together art, theology, and science much as the book itself attempts to create a common ground between these diverse modes of seeing and making sense of the world.

Find more faculty and alumni books on Washington Universitys bookshelf.

Read the rest here:
What does science tell us about Adam and Eve? - Washington University in St. Louis Newsroom

Read More...

Coronavirus threat to global Balanced Salt Solutions Market boosting the growth Worldwide: Market dynamics and trends, efficiencies Forecast 2024 -…

Wednesday, June 17th, 2020

Analysis of the Global Balanced Salt Solutions Market

A recently published market report on the Balanced Salt Solutions market highlights the pitfalls that companies might come across due to the unprecedented outbreak of COVID-19 (Coronavirus). Buyers can request comprehensive market analysis of Coronavirus and its impact on the Balanced Salt Solutions market to mitigate revenue losses.

This market research report on the Balanced Salt Solutions market published by Balanced Salt Solutions derives current insights about the competitive landscape of the Balanced Salt Solutions market. Further, the report unfolds detailed analysis of different segments of the Balanced Salt Solutions market and offers a thorough understanding of the growth potential of each market segment over the assessment period (20XX-20XX).

According to the analysts at Balanced Salt Solutions , the Balanced Salt Solutions market is predicted to register a CAGR growth of ~XX% during the assessment and reach a value of ~US$ XX by the end of 20XX. The report analyzes the micro and macro-economic factors that are projected to influence the growth of the Balanced Salt Solutions market in the coming decade.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2530274&source=atm

Key Insights Highlighted in the Report

Segmentation of the Balanced Salt Solutions Market

The presented report elaborate on the Balanced Salt Solutions market into different segments and ponders over the current and future business potentials of each segment. The report showcases the year-on-year growth of each segment and ponders upon the different factors that are likely to influence the growth of each market segment.

The various segments of the Balanced Salt Solutions market explained in the report include:

The following manufacturers are covered:Thermo Fisher ScientificLonza GroupDickinsonEMD MilliporeBectonCorning Life SciencesWheatonPromoCellSigma-AldrichBiological

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeBy product typeHanks Balanced Salt SolutionGeys Balanced Salt SolutionEarles Balanced Salt SolutionDulbeccos Phosphate Buffered SalineOtherBy end userResearch InstitutesPharmaceutical & Biotechnology Companies

Segment by ApplicationBiopharmaceuticalstherapeuticsStem Cell TechnologyDrug Screening & DevelopmentGenetic EngineeringCancer ResearchOthers

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2530274&source=atm

Important doubts related to the Balanced Salt Solutions market clarified in the report:

Why Choose Balanced Salt Solutions

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2530274&licType=S&source=atm

Read more here:
Coronavirus threat to global Balanced Salt Solutions Market boosting the growth Worldwide: Market dynamics and trends, efficiencies Forecast 2024 -...

Read More...

GM seeds: the debate, and a sowing agitation – The Indian Express

Monday, June 15th, 2020

Written by Parthasarathi Biswas | Pune | Updated: June 12, 2020 12:56:06 pm Genetic engineering aims to transcend the genus barrier by introducing an alien gene in the seeds to get the desired effects. (File Photo)

Last week, Shetkari Sanghatana the farmers union founded by the late leader Sharad Joshi announced fresh plans in its agitation for use of genetically modified seeds. In the current kharif season, farmers would undertake mass sowing of GM seeds for maize, soyabean, mustard brinjal and herbicide tolerant (Ht) cotton, although these are not approved. Farmers had carried out a similar movement last year, too.

What are genetically modified seeds?

Conventional plant breeding involves crossing species of the same genus to provide the offspring with the desired traits of both parents. Genetic engineering aims to transcend the genus barrier by introducing an alien gene in the seeds to get the desired effects. The alien gene could be from a plant, an animal or even a soil bacterium.

Bt cotton, the only GM crop that is allowed in India, has two alien genes from the soil bacterium Bacillus thuringiensis (Bt) that allows the crop to develop a protein toxic to the common pest pink bollworm. Ht Bt, on the other, cotton is derived with the insertion of an additional gene, from another soil bacterium, which allows the plant to resist the common herbicide glyphosate.

In Bt brinjal, a gene allows the plant to resist attacks of fruit and shoot borer.

In DMH-11 mustard, developed by Deepak Pental and colleague in the South Campus of University of Delhi, genetic modification allows cross-pollination in a crop that self-pollinates in nature.

Across the world, GM variants of maize, canola and soyabean, too, are available.

What is the legal position of genetically modified crops in India?

In India, the Genetic Engineering Appraisal Committee (GEAC) is the apex body that allows for commercial release of GM crops. In 2002, the GEAC had allowed the commercial release of Bt cotton. More than 95 per cent of the countrys cotton area has since then come under Bt cotton. Use of the unapproved GM variant can attract a jail term of 5 years and fine of Rs 1 lakh under the Environmental Protection Act ,1989.

Why are farmers rooting for GM crops?

In the case of cotton, farmers cite the high cost of weeding, which goes down considerably if they grow Ht Bt cotton and use glyphosate against weeds. Brinjal growers in Haryana have rooted for Bt brinjal as it reduces the cost of production by cutting down on the use of pesticides.

Unauthorised crops are widely used. Industry estimates say that of the 4-4.5 crore packets (each weighing 400 gm) of cotton sold in the country, 50 lakh are of the unapproved Ht Bt cotton. Haryana has reported farmers growing Bt brinjal in pockets which had caused a major agitation there. In June last year, in a movement led by Shetkari Sanghatana in Akola district of Maharashtra, more than 1,000 farmers defied the government and sowed Ht Bt cotton. The Akola district authorities subsequently booked the organisers.

Express Explainedis now onTelegram. Clickhere to join our channel (@ieexplained)and stay updated with the latest

Environmentalists argue that the long-lasting effect of GM crops is yet to be studied and thus they should not be released commercially. Genetic modification, they say, brings about changes that can be harmful to humans in the long run.

What is the movement about?

The Sanghatana has announced that this year they are going to undertake large-scale sowing of unapproved GM crops like maize, Ht Bt cotton, soyabean and brinjal across Maharashtra. Farmers who plant such variants will put up boards on their fields proclaiming the GM nature of their crop. Anil Ghanwat, president of the union, has said this action will draw attention to the need for introduction of the latest technology in the fields. He said farmers will not be deterred by any action taken against them by the authorities.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Explained News, download Indian Express App.

The Indian Express (P) Ltd

Read the original post:
GM seeds: the debate, and a sowing agitation - The Indian Express

Read More...

Gene-editing company raises 56M in Series A2 to advance gene-editing therapies for curing heart disease – Silicon Canals

Monday, June 15th, 2020

Gene editing is a type of genetic engineering and it is a relatively newer concept. It involves insertion, deletion, modification or replacement of DNA in a living organisms genome. Gene editing could be a powerful tool for helping people suffering from chronic ailments. Some companies are working tirelessly to employ gene editing for solving health problems and Cambridge, Massachusetts based Verve Therapeutics is one of them. The company has now secured 56M in Series A2 to advance gene-editing therapies for reducing the risk of coronary heart disease.

The latest series A2 round for Verve Therapeutics was led by companys existing investor GV, which was formerly known as Google Ventures. Furthermore, current investors ARCH Venture Partners, F-Prime Capital, and Biomatics Capital also joined the investment round. New investors Wellington Management and Casdin Capital also joined in. With the latest funding, the overall funds raised by the company touch a total of 109.5 million.

Coronary heart disease is said to be one of the leading causes of death in the U.S. and worldwide. Verve capital is developing a solution to tackle the issue and lower its risks in adults. It is doing so by developing one-time, gene-editing therapies that can safely edit targeted genes in the liver, which will result in permanent lowering of LDL cholesterol and triglycerides, which are key risk factors causing coronary heart disease. With the freshly acquired funds, the company will focus on advancing its lead program through IND-enabling studies and progress follow-on pipeline programs.

We are immensely grateful to our existing investors for their continued support and commitment to our bold vision to eradicate coronary heart disease, and are very pleased to welcome Wellington Management and Casdin Capital to our investor syndicate, says Sekar Kathiresan, M.D, co-founder and CEO of Verve. This financing is a testament to the tremendous work by the Verve team and will position us to rapidly advance our lead therapeutic candidate through IND-enabling studies and expand our pipeline of development programs. People with heart disease are in urgent need of new therapeutic options, and Verves research to date further underscores the transformative potential of gene editing as a therapeutic approach for these patients.

Image credits: Verve Therapeutics

Stay tuned toSilicon Canalsfor more European technology news

The rest is here:
Gene-editing company raises 56M in Series A2 to advance gene-editing therapies for curing heart disease - Silicon Canals

Read More...

What scientists are learning about COVID-19 from animals – WISHTV.com

Monday, June 15th, 2020

INDIANAPOLIS (WISH) Health experts say a vaccine is the worlds best hope to ending the coronavirus pandemic.

And while there are currently dozens of human clinical trials underway, other trials are enlisting animals. Some are house pets, some live in pastures, and others in tropical rain forests.

Ferrets

Ferrets are vulnerable to many respiratory illnesses found in humans, including lung cancer, cystic fibrosis and the novel coronavirus,thus making them great candidates for experimentation, scientists say.

Researchers now know ferrets can contract and transmit COVID-19. This has a lot to do with how the virus enters the body and attacks the lungs. The mechanism mirrors how COVID-19 attaches to human lungs, scientists say.

Scientists from the Commonwealth Scientific and Industrial Research Organization in Australia have started two pre-clinical trials to test a potential COVID-19 vaccine using the animal.

Monkeys

Scientists from The Jenner Institute at Oxford University began working on a coronavirus vaccine back in 2019. While its not for COVID-19, the virus responsible for this pandemic, its very similar.

The vaccine was tested at the National Institutes of Healths Rocky Mountain Laboratory in Montana. Scientists injected six rhesus monkeys with the 2019 vaccine and then exposed them to the novel coronavirus. Less than a month later, all six monkeys showed no signs of COVID-19.

Cows

Researchers are also looking to cows in an effort to develop a treatment. Scientists at SAB Biotherapeutics in South Dakota, through genetic engineering, created an embryo that contains parts of human chromosomes. The embryo is then implanted into the cow.

The resulting calf then grows into what scientists call a genetically humanized cow. The only overlap between the cow and a person is a portion of their immune system.

The genetically humanized cows are then injected with COVID-19. The cows immune system now similar to a persons would then attack the coronavirus. From there, scientists would look to see if the cows develop antibodies against it. The idea is that these antibodies would then be extracted from the cows blood and used as a drug to combat the coronavirus.

Original post:
What scientists are learning about COVID-19 from animals - WISHTV.com

Read More...

How Receptive are Consumers to Agricultural Biotech? – Food Institute Focus – Food Institute Blog

Monday, June 15th, 2020

After decades of being sidelined by consumers concerned over whether they were safe, foods made with genetically modified organisms, or GMOs, may finally find a place on more meal plates along with other new agricultural biotechnologies aimed at making plants drought- or flood-tolerant and increasing yields.

The changing climate and growing population are pressuring the food system, experts said. At the same time younger generations like Gen Z are interested in the environment and sustainability and are more likely to be open to eating food created with new technologies that could boost yields.

Consumers should think less about the technology and more about what we can do to enhance the sustainability of agriculture, said Pamela Ronald, PhD, professor in the department of plant pathology at the University of California at Davis. There will be different technologies, now and into the future. There is a critical challenge to feed the growing population without destroying the environment.

Dr. Roland and her colleagues developed a rice that can withstand the heavy flooding in Africa and Asia and increase yields. She coauthored a paper entitled Crop Biotechnology and the Future of Food that appeared in the May 19 issue of Nature Food on genetic tools to help increase food production.

By 2050 the global population is predicted to reach 9.7 billion. Meeting this higher food demand, if consumption practices and food waste do not change, requires estimated food production increases of 25% to 200%, she wrote. Cultivated crops using food technologies are part of the solution, she said.

Meanwhile, anti-GMO groups including the Organic Consumers Association in Finland, MN, and the Institute for Agriculture and Trade Policy in Minneapolis, MN, argue there isnt enough research yet on GMOs to assure they are safe to eat.

Some companies even use a non-GMO label as an advantage when marketing to consumers. Meat alternative company Beyond Meat utilized that label to distinguish itself from competitor Impossible Burger, which uses two genetically engineered ingredients: soy leghemoglobin and soy protein.

However, debates over GMO or non-GMO labeling are unlikely to fundamentally change consumers views of GMOs, said William Hallman, PhD, professor and chair of the Department of Human Ecology at Rutgers University, New Brunswick, NJ.

Sales of the Impossible Burger dont appear to be flagging because people are concerned about the fact that it has GMO-based ingredients, he said. In fact, it is more likely that people are attracted to the idea that both the Beyond and Impossible burgers are plant-based, which creates a health halo around the products.

He mentioned most consumers will freely admit they know little about GMOs or gene-editing technologies, so they are not changing their habits about eating GMO foods.

One of the pioneers of GMOs was Norman Borlaug, PhD, who in the 1950s created a disease-resistant, high-yield, semi-dwarf wheat that fed millions of people in Mexico and South Asia.

GMOs continue to be used to relieve famines and get more crop yield out of available land. In January, Zimbabwe quietly lifted its 12-year-old ban on GMO corn in an effort to avert a severe famine, according to Bloomberg News.

The current and anticipated challenges to the food system arent lost in the U.S. Three federal agencies in March got behind an effort to educate consumers about GMOs. The U.S. FDA, USDA, and EPA launched the Feed Your Mind program, which aims to answer questions about what GMOs are, how and why they are made, how they are regulated, and whether they are healthy and safe.

A GMO is a plant, animal, or microorganism that has had its genetic material modified, including transferring DNA from one organism to another. Apples, potatoes, and soybeans are among the many genetically modified foods that are available in supermarkets.

While foods from genetically engineered plants have been available to consumers since the early 1990s and are a common part of todays food supply, there are a lot of misconceptions about them, FDA Commissioner Stephen Hahn, MD, said when the initiative was launched. This initiative is intended to help people better understand what these products are and how they are made. Genetic engineering has created new plants that are resistant to insects and diseases, led to products with improved nutritional profiles, as well as certain produce that dont brown or bruise as easily.

The COVID-19 pandemic could have a role in consumer awareness of potential food shortages, even though distribution issues may be at the root of the problem now, said Oliver Peoples, PhD, president and CEO of Yield10 Bioscience of Woburn, MA, a company that uses the gene-editing technology CRISPR and other technologies to improve crop yields.

The public has gone to the grocery store and seen empty shelves, including basic staples like meats, chicken, and eggs, he said. This has forced many consumers to try genetically modified products that they might have not typically opted to buy before.

Furthermore, the Millennial and Gen Z generations are making a big difference in the acceptability of food made with technology because they are very focused on climate change and sustainability, said Dr. Peoples.

Marketing company Ketchum found that 77% of Gen Z consumers it polled are likely to try food made with technology and 71% are comfortable with its use to grow food (see Food Tech Consumer Perception table below).

This bodes well for food companies, as Gen Z is the newest generation of food consumers with purchasing power, said Bill Zucker, managing director of food at Ketchum.

By Lori Valigra, journalist based in Harrison, ME. Reach her at valigra@gmail.com.

Read more:
How Receptive are Consumers to Agricultural Biotech? - Food Institute Focus - Food Institute Blog

Read More...

Bit Bios enter button for the keyboard to the software of life nabs the company $41.5 million – TechCrunch

Monday, June 15th, 2020

Bit Bio, the new startup which pitches itself as the enter button for the keyboard to the software of life only needed three weeks to raise its latest $41.5 million round of funding.

Originally known as Elpis Biotechnology and named for the Greek goddess of hope, the Cambridge, England-based company was founded by Mark Kotter in 2016 to commercialize technology that can reduce the cost and increase the production capacity for human cell lines. These cells can be used in targeted gene therapies and as a method to accelerate drug discovery at pharmaceutical companies.

The companys goal is to be able to reproduce every human cell type.

Were just at a very crucial time in biology and medicine and the bottleneck that has become really clear is a scalable source of robust human cells, said Kotter. For drug discovery this is important. When you look at failure rates in clinical trials theyre at an all time high thats in direct contradiction to the massive advancements in biotechnology in research and the field.

In the seventeen years since scientists completely mapped the human genome, and eight years since scientists began using the gene editing technology known as CRISPR to edit genetic material, theres been an explosion of treatments based on individual patients genetic material and new drugs developed to more precisely target the mechanisms that pathogens use to spread through organisms.

These treatments and the small molecule drugs being created to stop the spread of pathogens or reduce the effects of disease require significant testing before coming to market and Bit Bios founder thinks his company can both reduce the time to market and offer new treatments for patients.

Its a thesis that had investors like the famous serial biotech entrepreneur, Richard Klausner, who served as the former director of the National Cancer Institute and founder of revolutionary biotech companies like Lyell Immunopharma, Juno, and Grail, leaping at the chance to invest in Bit Bios business, according to Kotter.

Joining Klausner are the famous biotech investment firms Foresite Capital, Blueyard Capital and Arch Venture Partners.

Bit Bio is based on beautiful science. The companys technology has the potential to bring the long-awaited precision and reliability of engineering to the application of stem cells, said Klausner in a statement. Bit Bios approach represents a paradigm shift in biology that will enable a new generation of cell therapies, improving the lives of millions.

Photo: Andrew Brookes/Getty Images

Kotters own path to develop the technology which lies at the heart of Bit Bios business began a decade ago in a laboratory in Cambridge University. It was there that he began research building on the revolutionary discoveries of Shinya Yamanaka, which enabled scientists to transform human adult cells into embryonic stem cells.

What we did is what Yamanaka did. We turned everything upside down. We want to know how each cell is defined and once we know that we can flip the switch, said Kotter. We find out which transcription factors code for a single cell and we turn it on.

Kotter said the technology is like uploading a new program into the embryonic stem cell.

Although the company is still in its early days, it has managed to attract a few key customers and launch a sister company based on the technology. That company, Meatable, is using the same process to make lab-grown pork.

Meatable is the earliest claimant to a commercially viable, patented process for manufacturing meat cells without the need to kill an animal as a prerequisite for cell differentiation and growth.

Other companies have relied on fetal bovine serum or Chinese hamster ovaries to stimulate cell division and production, but Meatablesays it has developed a processwhere it can sample tissue from an animal, revert that tissue to a pluripotent stem cell, then culture that cell sample into muscle and fat to produce the pork products that palates around the world crave.

We know which DNA sequence is responsible for moving an early-stage cell to a muscle cell, says Meatable chief executive Krijn De Nood.

If that sounds similar to Bit Bio, thats because its the same tech just used to make animal instead of human cells.

Image: PASIEKA/SCIENCE PHOTO LIBRARY/Getty Images

If Meatable is one way to commercialize the cell differentiation technology, Bit Bios partnership with the drug development company Charles River Laboratories is another.

We actually do have a revenue generating business side using human cells for research and drug discovery. We have a partnership with Charles River Laboratories the large preclinical contract research organization, Kotter said. That partnership is where we have given early access to our technology to Charles River They have their own usual business clients who want them to help with their drug discovery. The big bottleneck at the moment is access to human cells.

Drug trials fail because the treatments developed either are toxic or dont work in humans. The difference is that most experiments to prove how effective the treatments are rely on animal testing before making the leap to human trials, Kotter said.

The company is also preparing to develop its own cell therapies, according to Kotter. There, the biggest selling point is the increased precision that Bit Bio can bring to precision medicine, said Kotter. If you look at these cell therapies at the moment you get mixed bags of cells. There are some that work and some that have dangerous side effects. We think we can be precise [and] safety is the biggest thing at this point.

The company claims that it can produce cell lines in less than a week with 100 percent purity, versus the mixed bags from other companies cell cultures.

Our moonshot goal is to develop a platform capable of producing every human cell type. This is possible once we understand the genes governing human cell behaviour, which ultimately form the operating system of life, Kotter said in a statement. This will unlock a new generation of cell and tissue therapies for tackling cancer, neurodegenerative disorders and autoimmune diseases and accelerate the development of effective drugs for a range of conditions. The support of leading deep tech and biotech investors will catalyse this unique convergence of biology and engineering.

See original here:
Bit Bios enter button for the keyboard to the software of life nabs the company $41.5 million - TechCrunch

Read More...

If You Invested $1,000 in Fate Therapeutics’ IPO, This Is How Much Money You’d Have Now – The Motley Fool

Monday, June 15th, 2020

If you had invested $1,000 in shares of mid-cap biotech company Fate Therapeutics(NASDAQ:FATE) when it IPO'd, you would have close to $4,823.33 as of markets' close on June 11. That's an astonishing return on investment of 397.5%. In context, the S&P 500 returned 78.8% over the same period.

What's baffling, however, is that the stock's win streak has been entirely ignored by retail investors. In its most recent filings with the Securities and Exchange Commission, institutional investors accounted for almost 100% of the company's ownership. Even so, the company managed to garner much institutional interest despite only having its experimental therapies reach phase 1 status. Could the stock continue its winning streak and deliver riches to investors? Let's find out below.

Image Source: Getty Images

Fate Therapeutics has big buyers excited because it's at the forefront of developing the third generation of cellular immunotherapies. Immunotherapies are treatments that use the power of the body's own immune system to control and eliminate cancer. Currently, the method being investigated by biotechs and researchers around the world is chimeric antigen receptor T-cells (CAR T-cell) immunotherapy, which can help save lives but has a huge price tag.Indeed, after overhead costs, mark-ups, and a three-week manufacturing process, one course of CAR T-cell treatment can cost up to $1.5 million.

Luckily, this is where Fate Therapeutics comes to the rescue with its proprietary induced pluripotent stem cell (iPSC) technology. Using this method, a single stem cell clone can morph into more than 200 different types of cells via genetic engineering, which can then be mass-produced and stored. When cancer patients need a specific type of antibody in their systems, doctors would be able to request the corresponding iPSC on demand from a cell bank.

In previous articles, I discussed the effectiveness of two such therapies,NK100 and FT500, in phase 1 clinical trials. Let's examine yet another one of Fate Therapeutics' promising candidates, FT516.

FT516 is a natural-killer (NK) cell engineered from Fate Therapeutics' master iPSC line with a modified form of the CD16 receptor. Normally, tumor-killing activity from NK cells can be heavily impaired when these cells detach from their targets. FT516, however, is designed to resist detachment upon activation and have a higher affinity for currently approved antibodies that help target cancer cells.

In its phase 1 interim data release, one patient with acute myeloid leukemia who took FT516 (90 million cells per dose) for three weeks as a monotherapy with IL-2 cytokine (cells that regulate the activity of cancer-fighting T-cells) support showed no external evidence of leukemia after treatment.Furthermore, there was evidence of hematopoietic recovery (improvement in the ability to form blood cells of all types), and no circulating leukemia cells were observed in the peripheral blood. FT516 was also found to be well tolerated in this patient.

While the results are very good, observers may rightly point out that the therapy only worked on one patient and has not been compared to current standards of care. However, the patient who recovered after taking FT516 had previously failed multiple rounds of chemotherapy and treatment with standard of care. Hence, it's more likely than not -- save for a miracle -- that the experimental therapy kept the patient alive.

Overall, all three of Fate's pipeline candidates are set to release their clinical data by the end of 2022. Currently, Fate Therapeutics has more than $1.8 billion in potential payouts if these therapies are successful in the development and regulatory stage, and an additional $1.2 billion for hitting certain commercial milestones. The company also has $319 million in cash and investments, including a $100 million cash infusion from Johnson & Johnson's (NYSE:JNJ) Janssen subsidiary in April. Recently, the company closed another round of equity funding from Johnson and Johnson worth at least $214 million, a move that is highly indicative of the pharma giant's confidence in Fate Therapeutics' future prospects.

Image Source: YCharts

Compared to a quarterly net loss of $33 million, the company's capitalization is superb. I think Fate Therapeutics has some truly amazing candidates in its pipeline and is well positioned to enrich investors with a high risk tolerance.

Continued here:
If You Invested $1,000 in Fate Therapeutics' IPO, This Is How Much Money You'd Have Now - The Motley Fool

Read More...

How Coronavirus Pandemic Will Impact Nucleic Acid Isolation and Purification Market 2020: Industry Size, Outlook, Share, Demand, Manufacturers and…

Monday, June 15th, 2020

The Nucleic Acid Isolation and Purification Market research report enhanced worldwide Coronavirus COVID19 impact analysis on the market size (Value, Production and Consumption), splits the breakdown (Data Status 2014-2020 and 6 Year Forecast From 2020 to 2026), by region, manufacturers, type and End User/application. This Nucleic Acid Isolation and Purification market report covers the worldwide top manufacturers like (Agilent Technologies, Bio-Rad Laboratories, F.Hoffmann-La-Roche, GE Healthcare, Thermo Fisher Scientific, Abcam, Bioline, Biotechrabbit, BioWORLD, Danaher, Epicentre, Hamilton, New England Biolabs, Omega Bio-tek, Promega, Qiagen, Sigma-Aldrich, Takara Bio) which including information such as: Capacity, Production, Price, Sales, Revenue, Shipment, Gross, Gross Profit, Import, Export, Interview Record, Business Distribution etc., these data help the consumer know about the Nucleic Acid Isolation and Purification market competitors better. It covers Regional Segment Analysis, Type, Application, Major Manufactures, Nucleic Acid Isolation and Purification Industry Chain Analysis, Competitive Insights and Macroeconomic Analysis.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures)of Nucleic Acid Isolation and Purification[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2380946

Nucleic Acid Isolation and Purification Market report offers comprehensive assessment of 1) Executive Summary, 2) Market Overview, 3) Key Market Trends, 4) Key Success Factors, 5) Nucleic Acid Isolation and Purification Market Demand/Consumption (Value or Size in US$ Mn) Analysis, 6) Nucleic Acid Isolation and Purification Market Background, 7) Nucleic Acid Isolation and Purification industry Analysis & Forecast 20202026 by Type, Application and Region, 8) Nucleic Acid Isolation and Purification Market Structure Analysis, 9) Competition Landscape, 10) Company Share and Company Profiles, 11) Assumptions and Acronyms and, 12) Research Methodology etc.

Scope of Nucleic Acid Isolation and Purification Market:Nucleic acid isolation and purification is a procedure of molecular biology techniques such as cloning, sequencing, polymerase chain reaction and others. These techniques have various applications in the field of genetic engineering, life science research, forensics and molecular diagnostics.

Nucleic acid isolation and purification has provided information to forensic scientists based on downstream analysis and power to individualize biological evidence to match the criminal. Biological evidence such as blood and hair follicles are collected and stored helping forensic investigators to take out nucleic acid for analysis.

In addition, mRNA isolation and purification, RNA isolation and purification, plasmid DNA isolation and purification, total RNA isolation and purification, and PCR clean up. Nucleic acid isolation helps in processing of more sample in less time, minimizes nucleic acid loss ad degradation and increases laboratory efficiency and effectiveness. It also helps in purification of nucleic acid. Column based, reagent based, magnetic bead based and others are some important technology used in nucleic acid isolation and purification. These are used by hospitals, pharmaceuticals, academic research, diagnostic centers, biotechnology companies and food testing and laboratories.

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate foreach application.

Hospital Research Others

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

DNA Isolation and Purification RNA Isolation and Purification

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2380946

Geographically, the report includes the research on production, consumption, revenue, Nucleic Acid Isolation and Purification market share and growth rate, and forecast (2020-2026) of the following regions:

Important Nucleic Acid Isolation and Purification Market Data Available In This Report:

Strategic Recommendations, Forecast Growth Areasof the Nucleic Acid Isolation and Purification Market.

Challengesfor the New Entrants,TrendsMarketDrivers.

Emerging Opportunities,Competitive Landscape,Revenue Shareof Main Manufacturers.

This Report Discusses the Nucleic Acid Isolation and Purification MarketSummary; MarketScopeGives A BriefOutlineof theNucleic Acid Isolation and Purification Market.

Key Performing Regions (APAC, EMEA, Americas) Along With Their Major Countries Are Detailed In This Report.

Company Profiles, Product Analysis,Marketing Strategies, Emerging Market Segments and Comprehensive Analysis of Nucleic Acid Isolation and Purification Market.

Nucleic Acid Isolation and Purification Market ShareYear-Over-Year Growthof Key Players in Promising Regions.

What is the (North America, South America, Europe, Africa, Middle East, Asia, China, Japan)production, production value, consumption, consumption value, import and exportof Nucleic Acid Isolation and Purification market?

To Get Discount of Nucleic Acid Isolation and Purification Market:https://www.researchmoz.us/enquiry.php?type=D&repid=2380946

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

See the original post here:
How Coronavirus Pandemic Will Impact Nucleic Acid Isolation and Purification Market 2020: Industry Size, Outlook, Share, Demand, Manufacturers and...

Read More...

Egg-based coating preserves fresh produce – Feedstuffs

Monday, June 15th, 2020

Eggs that would otherwise be wasted can be used as the base of an inexpensive coating to protect fruits and vegetables, Rice University researchers have discovered.

Brown School of Engineering lab of materials scientist Pulickel Ajayan and colleagues have developed a micron-thick coating that solves problems both for produce and its consumers.

When the coating was applied to produce by spraying or dipping, it showed a remarkable ability to resist rotting for an extended period comparable to standard coatings like wax, but without some of the inherent problems.

The coating provides an outlet for eggs that never reach the market, the researchers suggested, as manufacturers reject 3% of the more than 7 billion eggs produced each year in the U.S. In fact, they estimated that more than 200 million eggs end up in landfills each year.

Reducing food shortages in ways that dont involve genetic modification, inedible coatings or chemical additives is important for sustainable living, Ajayan said. The work is a remarkable combination of interdisciplinary efforts involving materials engineers, chemists and biotechnologists from multiple universities across the U.S.

Along with being edible, the multifunctional coating retards dehydration, provides antimicrobial protection and is largely impermeable both to water vapor to retard dehydration and to gas to prevent premature ripening. The coating is all-natural and washes off with water.

If anyone is sensitive to the coating or has an egg allergy, they can easily eliminate it, Jung said.

Egg whites (albumen) and yolks account for nearly 70% of the coating, the researchers explained. The majority of the rest of the coating consists of nanoscale cellulose extracted from wood -- which serves as a barrier to water and keeps produce from shriveling -- a small amount of curcumin for antimicrobial powers and a splash of glycerol to add elasticity.

Lab tests on dip-coated strawberries, avocadoes, bananas and other fruit showed that they maintained their freshness far longer than uncoated produce. Compression tests showed that coated fruits were significantly stiffer and firmer than uncoated fruits and demonstrated the coatings ability to keep water in the produce, thus slowing the ripening process.

An analysis of freestanding films of the coating showed it to be extremely flexible and able to resist cracking, allowing better protection of the produce. Tests of the films tensile properties showed it to be just as tough as other products, including synthetic films used in produce packaging. Further tests proved the coating to be nontoxic, and solubility tests showed that a thicker-than-usual film is washable. Rinsing in water for a couple of minutes can completely disintegrate it, Ajayan said.

The researchers continue to refine the coatings composition and are considering other source materials.

We chose egg proteins because there are lots of eggs wasted, but it doesnt mean we cant use others, said co-corresponding author Muhammad Rahman, a research scientist in Ajayans Rice lab who mentored and led the team.

Jung noted that the team is testing proteins that could be extracted from plants rather than animal production to make coatings.

Continue reading here:
Egg-based coating preserves fresh produce - Feedstuffs

Read More...

People with blood type O more protected against COVID-19 – studies – The Jerusalem Post

Monday, June 15th, 2020

People with blood type O have less of a chance of getting the COVID-19, according to a number of studies published all over the world during the pandemic. Meanwhile, people with type A might be more vulnerable.

After the pandemic broke out, scientists and doctors alike became puzzled by one question, why are some people more susceptible to contracting, and even succumbing to the disease than others?

According to their blog they did a study that contained more than 750,000 participants. Their preliminary data suggests that O blood type appears to be protective against the virus, and people with that type are between 9-18% less likely that other individuals to have tested positive for the COVID-19 virus.

But how does blood type actually play a role in infection?

Their study included extracting DNA samples from 1,980 COVID-19 patients who were hospitalized for respiratory failure. They scanned the samples using a rapid technique called genotyping, and looked at nearly nine million genetic letters. The researchers then carried out the same experiment on 2,205 blood donors with no evidence of COVID-19. They found that the ill patients shared a number of similar genetic variants compared to those who were not ill.

The scientists were looking for spots in the genome called loci, which they ultimately found. In one of those spots is the gene that determines blood type. Their analysis showed higher risk for A-positive individuals and a protective effect for blood group O.

Blood type is determined by specific sugar molecules that are added to proteins or lipids on our blood cells and other cell types, according to Chemical Science and Engineering news. Those that are in the A blood type group carry A sugar antigens, the same goes for people in the blood type B with B-antigens, however O blood type have neither.

This means that the immune systems of people with type A blood develop antibodies for B antigens, people with type B blood have antibodies for A antigens, and people with type O blood have antibodies for both. Blood type influences blood clotting and a growing body of evidence suggests that COVID-19 pathology often involves overactive blood clotting. People with type O blood have lower levels of proteins that promote blood clotting.

Read this article:
People with blood type O more protected against COVID-19 - studies - The Jerusalem Post

Read More...

Rick And Morty: 5 Times Rick Was A Genius In The Show (& 5 Times He Was A Doofus Rick) – Screen Rant

Monday, June 15th, 2020

Rick And Morty has always sold Rick as being the smartest man in existence, and while he can be a genius, sometimes he really is a doofus Rick.

Anyone who has sat through all four seasons ofRick and Mortyought to know by now that Rick Sanchez is an alcoholic cesspool of unresolved issues-- he's nowhere near as perfect as he narcissistically wants to appear. In that regard, he has made plenty of conscious mistakes all throughout the show.

RELATED:Rick And Morty: 10 Ways That Evil Morty Could Get His Revenge

At the same time, Rick's also an undeniable genius especially when it comes to his inventions and a general understanding of the parallel universes. Itdoes seem that it can be tiring to be a genius all the time and sometimes Rick unleashes brain farts more obscene than his actualgas. Here are five of those strokes of genius and five of those Doofus Rick moments to prove Rick is only human.

Turning himself in during the episode "Rickshank Redemption"was a shocking moment considering that Rick has always been selfish. It was rather too good to be true-- and it was. Turns out it was Rick's plan all along to hit four birds with one stone.

The first goal was to trash the Galactic Federation, the second was to rope the Citadel into fighting the Federation, the third was to make Beth divorce Jerry, and the fourth was... to get his fix of the Mulan Szechuan McNugget sauce. All four plans were achieved in one fell swoop, it was Rick at his strategic peak.

Speaking of highs, Rick's intellect also has its lows. By far one of the worst blunders he made was making a love potion for Morty which turned into flu that mutated everyone into failedAnimorphscharacters.

RELATED:Rick And Morty: 5 Reasons The Show Could Dip In Quality With So Many Episodes (& 5 It Wont)

Apparently, Rick was not that well-versed or good enough in biochemistry or genetic engineering and merely made wild guesses for his potion. The result was ruining dimension C-137 and scarring Morty permanently.

One of the biggest problems of humanity at the moment is finite resources, specificallyfor power/electricity. Rick knew this well enough and was able to circumvent the problem by making an infinite power source in the form of a mini-universe trapped inside his car battery.

It wasn't foolproof though but one has to give him credit for solving mankind's million-year-old problem. Funny thing is, Rick could have used it to advance humanity into its next technological stages but chose to be selfish and use it only for his car battery.

One of the latest displays of Rick's dwindling mojo is during the "Vat of Acid" episode where his plan consisted of faking death against gangsters using a vat of acid. Of course, it's for comedic value and the plot as to why he chose to follow through with that plan.

RELATED:Rick and Morty: 10 Worst Things Evil Morty Has Done

Still, Rick's vat of acid trick was not only boring but it also didn't make sense. Turns out Rick could have easily dealt with the alien gangsters without any consequences. Even Morty thought it was unimaginative and even called Rick "senile" for coming up with it.

Rick and Mortyhas its own version of the Avengers in the form of the rather dysfunctional and rag-tag Vindicators. They're no slouch, however, and some of them are powerhouses in their own right, capable of destroying planets even.

That didn't matter much for Rick as he was able to lay out an elaborate plan to kill them all or make them fight one another. The impressive part was that he did all of this while he's drunk

If Jerry had a dollar for every time Rick brings Earth closer to an apocalypse, he'd wouldn't be so worried about being unemployed. It just so happens that Rick does that casually, most notably in the episode "Total Rickall."

RELATED:Rick and Morty Characters Sorted Into Their Hogwarts Houses

It's where Rick casually brought home some parasites from space that implant fake memories telepathically and take over whole worlds. It's been proven that Rick did it by Justin Roiland(co-creator and Rick voice actor) himself. It led to Beth shooting Mr. Poopybutthole, that's bad enough.

Found finally met his match and one of the most competent adversaries he has in the form of Zeep Xanflorp who lives in the car battery's mini-universe. Turns out he was as smart as Rick and was even younger.

When the two of them got trapped in a jungle with nothing but twigs and rocks, Rick was able to build weapons and even mechs out of raw resources with no laboratory. It goes to show that Rick doesn't need his inventions to thrive.

When it comes to facing his own psychological or mental issues, Rick turns from a bright and calculating scientist to a scared toddler. He even goes as far as to create his own problems just to avoid going into therapy.

RELATED:Rick And Morty: The 15 Best Episodes So Far (According To IMDb)

That goes to show just how low Rick's emotional intelligence but he turned himself into an initiallyhelpless pickle in order to avoid a mere hours-long counseling session. It was fun to watch but one just has to wonder what was going on in Rick's "rational" mind.

Whether the Rickest Rick inRick and Mortyinvented the portal gun or not, he surely knows how to maximize it. Not only does he shoot his way into other dimensions for more knowledge or better resources than the Earth could offer but also sometimes weaponizes the Portal Gun in clever ways.

Rick also knows how to recharge the Portal Gun so it's more than likely that he did invent it, much like other Ricks in other dimensions as well. It's arguably Rick's greatest invention and even his greatest weapon, apart from his brain.

Turning himself into a pickle or concocting a lame vat of acid idea weren't the most questionable Rick decisions ever. That award goes to what he did with the "real" Beth and the clone Beth in the finale of Season 4.

Rick, like the awesome dad he is, made his computer shuffle the two Beths; now neither he nor anyone else can know which is the real one. Oddly enough, there was no need for him to do that since he erased it from his memory anyway.

NEXT:Rick And Morty: 10 Un-Rickest Versions Of Rick In The Series

Next Friends: 5 Times Monica Was An Overrated Character (& 5 She Was Underrated)

Sid Natividad likes movies so much as to choose the risk of urinary tract infection than miss a few minutes of post-credit Easter eggs, that shows the extent of his dedication. He is well-versed in multiple fandoms that gravitate toward the edgy and nihilistic spectrum of the internet culture. Outside of being a writer for Screen Rant, he also works as a journalist and has risked his life for mere warzone photos.

Continue reading here:
Rick And Morty: 5 Times Rick Was A Genius In The Show (& 5 Times He Was A Doofus Rick) - Screen Rant

Read More...

Fat alternative Epogee gains traction: ‘The low-fat ship sailed 25 years ago, this is not about low fat, it’s about caloric reduction’ -…

Monday, June 15th, 2020

Products already on the market containing Epogeeinclude enrobed caramel clusters and a fast-growing low-calorie ice cream brand delivering asuper-premium creamy mouthfeel,Epogee chief commercial officer Jayme Caruso told reporters in a briefing on Wednesday.

We have a customer about to launch a peanut spread and a chocolate hazelnut spread with EPG and we expect to see many more products hitting the market with EPG in the coming months.

EPG (esterified propoxylated glycerol) which be listed on food labels as EPG (modified plant-based oil) - can be used to replace up to 85% of the fat in scores of applications from confectionery to baking mixes, said Caruso, who said the FDA had just confirmed it had no objections to extending a GRAS determination for EPG to include potato chips, corn-based savory snacks, chicken nuggets, plant-based protein products, dairy analogs, and beverages/beverage bases.

To make EPG, the company splits rapeseed oil (although other vegetable oils can also be used) into glycerin and fatty acid, inserts a food-grade link, and reconnects them (see box below for details).

The modified fat (EPG) has a high melting point of 102F, which means that it doesnt liquify when it passes through the body (which typically has a temperature of around 98.6F) and has the consistency of soft candlewax, Caruso told FoodNavigator-USA.

It largely resists digestion because digestive enzymes are prevented from breaking it down, so hardly any of its calories are released, added Caruso, who is talking to potential partners from leading CPG brands to disruptive startups.

To put this into perspective, 1g of fat contains 9 calories, while 1g of Epogee contains 0.7 calories.

Unlike Olestra (which had a lower melting point and messy side effects) or fat replacers made from sugars, gums, starches or fibers (which provide bulking, humectancy and mouthfeel but many firms dont want to include on the ingredients list), EPG functions like fat in food products and in the human body because its made from fat, said Caruso.

In a nutshell, he said, EPG is unique in the food formulation space because its analternative fat, not a fat substitute EPG looks feels, tastes, and functions like fat because its made from fat, it just doesnt deliver the calories.

While fat reduction and replacement might have been all the rage in the 80s and 90s, consumers today some of whom are actively embracing high fat keto diets are more worried about sugar, acknowledged Caruso.

But theyre also worried about their weight, and they are still paying attention to calories, and given that fat contains a lot more calories per gram (9) than carbs or protein (4), it is the easiest target to drive calories out of products, he said.

The low-fat ship sailed 25 years ago, but this is not about low fat, its about caloric reduction.

And if food culture has undoubtedly changed since the technology behind EPGs was first developed three decades ago, most Americans are still consuming more calories than they are burning off, and many of them come from fat, added Caruso.

There is currently nothing like this is on the market. We have two products, a confectionery EPG with a very sharp melting curve designed to mimic cocoa butter or fractionated palm kernel oil, and our workhorse spreadable EPG, which works in all of the other applications.

As to whether EPG would be considered clean label, theres no simple answer as this is not a legally defined term, said Caruso, although he conceded that some natural and organic brands might not be interested.

However, brands that are trying to appeal to calorie-conscious consumers are particularly excited by Epogee's potential to cut calories but also eliminate ingredients such as gums, starches and binders, preservatives and flavor enhancers that are often used in low calorie or low fat foods, he said.

The road to commercialization has been lengthy for EPGs, which were first developed in the 1980s by ARCO Chemical Company, which teamed up with Bestfoods to explore their potential as fat replacers in foods.

However, Bestfoods withdrew from the joint venture shortly thereafter, and work did not resume until late 2003 when the technology was assigned to a non-profit affiliated with Kansas State University. A new partner, Choco Finesse, LLC, was later granted development rights and changed its name to Epogee.

'Not another Olestra'

Epogee is not anotherOlestra(a hybrid molecule of sucrose esterified with eight fatty acids from Procter & Gamble that attracted a wave of negative PR over its messy side effects... notably anal leakage), says founder and CTO David Rowe.

"We got to learn from their experiences and essentially avoid some things that they did but we also have better chemistry. Our product is safer in terms of things like vitamin depletion[Epogee does not inhibit the absorption of fat-soluble vitamins], but another key thing is that Epogee is made from fat and tastes like fat.

Olestra had kind of a weird mouthfeel and for people old enough to remember the potato chips, they didnt quite taste like potato chips, but French fries or donuts made with Epogee will actually beat regular French fries or donuts[on taste/mouthfeel].

What are EPGs?

EPGs are a family of fat- and oil-like substances that resemble triglycerides in structure and appearance, but have been modified to prevent or limit their digestion when consumed in food.

How is Epogee made?

*According to aGRAS noticesubmitted to the FDA in 2015, esterified propoxylated glycerol (EPG) is produced by a three-step process: First, fats and oils are split into glycerol and fatty acids. Next, glycerol is reacted with propylene oxideto produce glycerol with propyleneglycol units (PGUs) inserted on its hydroxyl groups. Finally, the propylene glycol-substituted glycerol is reacted with fatty acids to produce EPG, which largely resists digestion because the PGUs prevent the digestive enzyme lipase from breaking down the fat.

Is it safe?

The FDA has no questions regarding the GRAS status of EPG for multiple food applications including confectionery products; frying; baked goods and baking mixes; frozen desserts and mixes; nut products (including peanut butter); grain products; pasta; granola and snack bars; sauces and gravies; soft candy; snack foods (potato chips, corn-based savory snacks, chicken nuggets); plant-based protein products; dairy product analogs; beverages/beverage bases; coffee, and tea.

EPGs have been evaluated for safety at levels as high as 150 grams per day.

How is it labeled?

Epogee - the brand name for EPG (esterified propoxylated glycerol) can be listed on food labels as EPG (modified plant-based oil).

While the word modified might conjure up images of genetic engineering (which isnotinvolved in its production), Epogee has not experienced any pushback from manufacturers or consumers on the name, claimed Caruso, who noted that modified starch is a common term on food labels.

See original here:
Fat alternative Epogee gains traction: 'The low-fat ship sailed 25 years ago, this is not about low fat, it's about caloric reduction' -...

Read More...

USDA revised regulations of GMO and gene edited plants. Here’s what it means. – Genetic Literacy Project

Wednesday, June 10th, 2020

The long-awaited updates from the United States Department of Agriculture (USDA) to its genetically engineered (GE) organism regulation have been issued. This final rule completed a more than 10-year process started back in 2008 to revise regulations promulgated in 1987. This article discusses these new regulations and some of their potential impacts. Overall, the rule ignores concerns raised by some industry, consumer and environmental groups that the new regulations, including an option for developers to self-determine whether their products are regulated, and could lead to adverse environmental and/or agricultural impacts, potential food safety risks, trade disruptions and a lack of consumer acceptance of new food technologies.USDA oversight from 1987 to the present

To understand the USDAs new regulation of GE plants, it is important to know how the agency has regulated GE plants since 1987. USDA regulates the import, interstate movement, and environmental release of GE plants under its legal authority to manage plant pests under the Plant Protection Act. A plant pest is any organism that can directly or indirectly injure, cause damage to, or cause disease in any plants or plant product. Under USDA regulations, a GE plant has been considered a potential plant pest if any of its newly introduced DNA came from an organism on USDAs list of plant pests, or if the method of introducing DNA into the plants genome involved an organism on USDAs list of plant pests. For example, if a GE plant was developed using the plant pest Agrobacterium to introduce new DNA, as many are, it was regulated. However, if the same DNA were introduced using the gene-gun method of transformation, USDA would not regulate the GE plant.

Under those regulations (found at 7 CFR part 340), developers were required to submit their GE plant products to one of three oversight processes before environmental release.

The first process, known as notification, is used to regulate field trials of low-risk GE plants. The applicant provides the USDA with information detailing its trial and the agency has 30 days to decide whether to permit the trial to proceed. As many as 1,000 field trials are authorized yearly using this procedure.

The second process is permitting, which requires a more detailed application for any outdoor planting (e.g., field trial) of higher-risk GE plants. After reviewing the application, USDA may issue a permit authorizing the release. The USDA has issued hundreds of permits since 1987.

The third process involves a petition for non-regulated status, where a developer requests the USDA to determinebased on evidence from field trialsthat the GE plant presents no plant pest risk and no longer requires regulation. The petition process is the primary path to commercialization and more than 140 plants have been deregulated.

For each regulatory process, the USDA is ensuring that the GE plant is not going to become a plant pest and cause harm to agricultural interests.

Up until 2011, every GE plant tested outdoors either submitted a notification or received a permit, and all commercialized plants satisfactorily completed the petition process. Then, in 2011, the USDA established a process whereby GE seed developers could ask the agency whether the GE plants they were developing required regulation, or whether they were exempt because they did not involve any plant pest components. The USDA responded to these Am I regulated? inquiries stating whether the GE plant was not regulated and could be planted without oversight. By the end of 2019, USDA determined that more than 85 plants did not fall within its regulatory authority and are exempt from oversight. So, over the last eight years, we have seen a decrease in how many GE plants USDA regulates.[1]

The new rule (called the Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient, (SECURE) Rule), which will be implemented over the next 18 months, applies to organisms produced through genetic engineering, which is defined to include techniques that use recombinant, synthesized, or amplified nucleic acids to modify or create a genome. This broad definition includes classical genetic engineering, which add one or more new genes to organism (transgenics, or what consumers consider GMOs), and newer gene editing techniques such as CRISPR, which can make edits within an organisms existing genome.

While the definition captures all GE plants, the USDA exempts many of them from any oversight. First, it exempts products with a single sequence deletion, substitution, or addition (if the addition is from the plants gene pool). Second, it exempts any GE plant that has the same plant-trait-mechanism of action as any GE plant previous regulated by the USDA. This means that if the USDA previously regulated a GE plant, such as an glyphosate-tolerant variety of corn, a new GE glyphosate-tolerant corn is exempt if it employs the same mechanism of action (meaning it biologically operates the same way to provide tolerance). Developers can self-determine whether they qualify for these exemptions; confirmation of their self-determination from the USDA is not required and the agency need not be informed.

If a GE plant is not exempt, the developer can either: (1) apply for a permit if the GE plant has potential plant pest risks; or (2) seek a Regulatory Status Review (RSR). The RSR starts with an initial 180-day process where the USDA determines if the GE plant has any plausible plant pest risks. That initial RSR step is a closer look at the GE plant than the current am I regulated? process, but less detailed than the process used for petitions for non-regulated status. The USDA stated that the initial review does not require any plant-specific laboratory or field-test data. If the USDA decides there are no plausible risks, it sends a letter to the developer stating the plant is not regulated and publishes the letter on its website. If the USDA cannot conclude that there are no plausible risks, then the developer can either: (1) request that the USDA conduct the second part of the RSR, which is detailed evaluation of potential plant pest risks that can take up to 15 month); or (2) apply for a permit. The more lengthy and detailed RSR evaluation is comparable to the current petition for non-regulated status process and ends in the USDA determining either that the GE plant is not regulated or that it needs a permit. If a developer receives a permit from the USDA, any outdoor planting (e.g. a field trial or a commercial planting) is subject to restrictions to prevent inadvertent release into the environment and any adverse plant pest impacts. These are the same restrictions that virtually all GE plants were subject to prior to 2012 under the notification and permitting processes. Only GE plants that receive permits have any continued USDA oversight.

The exemptions are one worrisome aspect of the new SECURE rule. First, they are not supported by scientific evidence showing that these categories of GE plants do not pose risks. Instead, the USDA states that since a single deletion, substitution or addition produces a plant that could be achieved by conventional breeding methods, and because conventionally bred plants have not raised plant pest risks, gene-edited plants that are the same as products that could be achieved through conventional breeding will not pose plant pest risks. The problem with this argument is that a science-based regulatory system should base its oversight on whether the plant possesses traits that make it a potential plant risks, not the plants method of production. One reason the USDA revised its rules was to focus on the properties of a product, not how it was developed, yet that is the very approach these exemptions enshrine. While many, if not most, plants with a single deletion may not present any plant pest risks, if one does, shouldnt USDA regulate it?

The second concern is that the developer self-determines if its product qualifies for an exemption. This sets up an inherent conflict of interest because developers have financial incentives to determine themselves exempt. While some developers will diligently determine the regulatory status of a GE plant, others may not. In addition, when a developer self-determines its product is exempt, neither the USDA nor the public know that the GE plant is being released into the environment and entering the food supply because there is no requirement to notify the agency of ones self-determination. If the USDA does not know which GE plants are self-determined as exempt, how can it confirm that the determination is correct?

One positive of the new rule is the agencys decision to limit the exemptions to single edits. The USDA reasons that while a single edit mimics a product that can be produced through conventional breeding methods, the same is not true for products with multiple edits. Therefore, if a developer makes two or more edits, the developer must apply for a permit or ask for an RSR. The first gene edited commercial product in the USCalyxts high oleic soybean, which the USDA exempted under the am I regulated? processwould not be exempt under the new rules because it has two edited genes. If most gene-edited products end up having two or more edits, the exemptions may have limited applicability.

While multi-edited products are not automatically exempt, the USDA is likely to find in the initial step of the RSR process that many do not pose any plausible plant pest risk. So the result may be the samethese products are not regulated. However, at least the initial RSR determination (instead of a developer self-determination), is made public, so stakeholders will know which multi-edited products are entering the market.

The USDA states that one goal of its revisions is to provide regulatory relief, and the final rule clearly achieves that. Many GE plants that historically required containment for field trials through either the notification or permitting process will no longer be subject to any substantive regulation. They either will be exempt or deemed to have no plausible plant pest risks through the initial step of the RSR process. What this means in practice is that GE plant developers (both private developers and academic scientists) can conduct field trials without any confinement conditions that ensure the GE plants do not persist in the environment after the trial is completed. The USDA stated in its proposed rule that it hopes developers voluntarily continue confinement measures, but that may or may not happen. GE plants have escaped from field trials with USDA oversight in the past and the likelihood of that happening will only increase without USDA oversight. That could mean new proteins inadvertently entering our food supply before they are deemed safe for human consumption. Experimental GE plants persisting in the environment after a field trial is concluded could also harm non-target organisms. Finally, if an unregulated GE plant escapes from a field trial and enters the export market, it could result in rejection of the US commodity because the experimental plant has not been approved in the importing country.

The final rule also fails to provide needed transparency on GE plants that will be commercialized. The USDA, food industry and consumers will be at the mercy of developers to make public information about products that they have deemed exempt. How will the food industry know which foods contain GE plants to ensure they are complying with export market legal requirements? How will food manufacturers and retailers answer questions from consumers asking whether their products contain ingredients from GE or gene-edited plants? If consumers are unable to access information about which GE plants are commercialized, will they become skeptical about those products and their safety? The lack of transparency inherent in the rule could result in international trade problems and misinformed consumers.

GE plants have provided benefits to farmers, the environment and consumers and are likely to continue to do so in the future. However, the USDA rule could impact the food industrys acceptance of those products and fuel consumer suspicions about biotech crops and foods.

[1] While the USDA is the primary agency regulating GE plants, the FDA and EPA regulate subsets of GE plants. If a GE plant is used for food or feed, the FDA regulates it under a voluntary consultation process set up under the Federal Food, Drug and Cosmetic Act. If a GE plant produces a pesticide, the EPA regulates it as a plant-incorporated protectant under the Federal Insecticide, Fungicide, and Rodenticide Act.

Original post:
USDA revised regulations of GMO and gene edited plants. Here's what it means. - Genetic Literacy Project

Read More...

UNC professor leading project to develop high school science lessons on COVID-19 – The Daily Tar Heel

Wednesday, June 10th, 2020

By integrating real world issues into the classroom, Sadler said students can see how the material theyre learning can translate to bigger picture issues and inform important decisions in their lives, which he hopes is achieved through the instructional materials his research team and partner teachers designed.

While Sadler said his team is still working this summer to develop and refine more lessons to form a coherent instructional unit that teachers can use over the course of a week or two in their classrooms, some early versions of activities have already been tested in a few classrooms.

Sadler said one of the activities that has been created shows how social distancing can impact viral spread through a modeled simulation that allows students to manipulate variables to see likely outcomes. Another activity is intended to help students develop a set of skills that can be used to analyze their information sources.

Sadler said all activities will be developed with enough flexibility to be suitable for both in-person or online instruction, due to the uncertainty of returning to the traditional classroom setting in the fall.

As the materials are used in classrooms, the research team will collect data through questionnaires and surveys to gauge students understandings of COVID-19, their interests and their use of information sources.

Based on his initial findings, Sadler said in general, there was greater student interest in learning about the international health crisis than the business as usual curriculum.

Patty Berge, a career technical education biomedical teacher at East Chapel Hill High School, said she felt it was important to address COVID-19 in the classroom since the virus was impacting students lives so dramatically.

Berge said she saw her students knowledge of the pandemic and its impact on their lives improve as a result of tying her curriculum to COVID-19. In collaboration with fellow biomedical teachers at her school, she said she created a few activities for students to delve into facts about COVID-19, the news surrounding it and ways to prevent outbreaks.

There's so much misinformation and disinformation out there about COVID, that it really is our responsibility to make sure that we're teaching the kids to go to the right resources and find the correct information and get the evidence to support what they're saying versus just repeating what they heard somebody else say, which has been a big issue, Berge said.

Margaret Burns, a science teacher at Jordan High School in Durham, said her students showed interest in learning about COVID-19 and found that a lot of them were doing their own research on the virus.

Like Berge, Burns said she thought it was important to remind students where accurate information can be found. Burns said she showed students the Centers for Disease Control and Prevention website and discussed how to understand its guidance and apply their knowledge.

Its definitely going to be something that we talk about in classes for a really long time, Burns said. It is something that's a shared experience by everyone at this point.

As teachers develop lesson plans this summer, Kimberly Manning, a science teacher at East Chapel Hill High School, said COVID-19 will be a part of her instruction and many others in the fall. While science is perhaps the easiest subject to connect to the pandemic, she said history teachers at her school also addressed it from a historical and social justice perspective.

We will always walk hand in hand with diseases, but we as a people, collectively, we have to be able to deal with it, learn about it, decode it and institute practices that are going to allow us to still live and coexist, Manning said. So, as teachers, as educators, we have to make it a part of what we do.

university@dailytarheel.com

Read more from the original source:
UNC professor leading project to develop high school science lessons on COVID-19 - The Daily Tar Heel

Read More...

Swarm of MILLIONS of gene-hacked mosquitoes will be unleashed across USA to wipe out malaria with death sex – The Sun

Wednesday, June 10th, 2020

MUTANT mosquitoes created in a lab to stop the spread of deadly diseases like malaria will be unleashed across the US this summer.

The gene-hacked bugs, crafted by UK biotech company Oxitec, are designed tokill off or reduce local populations of mosquitoes by mating with them.

3

Mosquitoes carry diseases like dengue, Zika and malaria which are then passed to anyone bitten by the creepy crawlies.

While the technology has shown promise in lab experiments, experts warn the scheme could go horribly wrong out in the wild.

"These strategies hold considerable potential benefits for the hundreds of millions of people impacted bymosquito-borne diseaseseach year," a group of scientists and ethicists wrote in The Conversation.

"However, we are concerned that current government oversight and scientific evaluation of genetically-modified mosquitoes do not ensure their responsible deployment."

3

Oxitec's controversial scheme was in May approved for "experimental use" in Florida and Texas by the US Environmental Protection Agency.

Starting this summer, millions of genetically-modified (GM) male mosquitoes will be released every week over the next two years.

When the lab-bred bugs are released and mate with wild females, their female offspring die.

Only female mosquitoes bite, meaning Oxitec's male-only insects won't spread diseases to people.

What is gene editing?

Here's what you need to know

Over time, repeated, large-scale releases of the modified insects should drive the temporary collapse of wild populations.

This should halt the spread of nasty diseases carried by mosquitoes, potentially saving thousands of lives.

Mosquito-borne illnesses like malaria are on the rise in the southern United States as climate change pushes bug populations up from South America.

Scientists are concerned about the lack of oversight for Oxitec projects in Florida and Texas.

For its part, Oxitec said in a statement that the article is The Conversation contained "a number of false or baseless claims".

3

The company has run into trouble before.

In Brazil, an Oxitec project spectacularly backfired after millions of the GM bugs were released into neighbourhoods in Jacobina.

Some scientists believe the project accidentally created a super-resistant mosquito species that's tougher to kill than before.

Oxitec's work has been heavily criticised by Friends of the Earth, a charity dedicated to protecting the environment.

Back in 2012, Friends of the Earth's Eric Hoffman said: "Trials of its mosquitos must not move forward in the absence of comprehensive and impartial reviews of the environmental, human health and ethical risks."

In a statement at the time, Friends of the Earth said: "The GM mosquitoes are intended to reduce the wild population by mating with naturally occurring mosquitoes and producing progeny which dont survive, thus reducing the population and therefore the transmission of the tropical disease dengue fever.

"The company has been widely criticised for putting its commercial interests ahead of public and environmental safety.

"Its first releases of GM mosquitoes took place controversially in the Cayman Islands, where there is no biosafety law or regulation.

"Oxitec staff have been closely involved in developing risk assessment guidelines for GM insects worldwide, leading to concerns about lack of independent scrutiny and conflict of interest."

LOST AND FOUNDLost Roman city revealed using radar uncovering temple, streets and sewers

AIR FAIR?Samsung invents Apple AirPods rivals that look like tiny BEANS in your ears

PLAN IT!How to see planets Jupiter, Saturn AND Mars rising in sky tonight with naked eye

SPACE STORMSaturn has a mystery 'mega storm' shaped like a perfect hexagon

Exclusive

PLAY TIMEPS5 design revealed? Stunning 'first look' images show leaked Sony sketches in 3D

OUT OF JUICEDelete THESE 22 dodgy apps to save your phone's battery life

In other news, Nasa could create "GM astronauts" designed to be super-strong and feel no pain.

Scientists are trying to make grey squirrels extinct in Britain through genetic engineering.

And, breeding "super-cows" that fart less is the latest bonkers plot to halt climate change.

We pay for your stories! Do you have a story for The Sun Online Tech & Science team? Email us at tech@the-sun.co.uk

Read more:
Swarm of MILLIONS of gene-hacked mosquitoes will be unleashed across USA to wipe out malaria with death sex - The Sun

Read More...

China Could Have Coronavirus Vaccine for Emergency Use As Early As This Autumn, Expert Says – Science Times

Wednesday, June 10th, 2020

Zhong Nanshan, China's top respiratory expert who discovered the SARS 2003, now plays a key role in the national COVID-19 policy. He said that it is impossible for any nation to reach herd immunity as it will cost millions of lives.

Nanshan estimates that 60% to 70% of the country's populationto be infected by the virus, which can cause a 30 to 40 million death toll.

That means the only way to defeat COVID-19 is to vaccinate all people. He said that vaccines for use in emergencies would be available as early as this autumn, but it could take at least two years for large-scale use.

It is similar to what Anthony Fauci, head of US National Institute of Allergy and Infectious Diseases, said that 100 million doses of the vaccine might be ready before the year ends and the clinical trials.

Last month, the Chinese Center for Disease Control and Prevention's head, Gao Fu, said that they are already drafting guidelines to determine the individual eligible to receive the vaccine when to take them, and what qualifies an emergency use.

Presently, there are five vaccines under clinical testing in China. One of them is developed by the Beijing Institute of Biological Products, published in its preclinical data on the journal Celllast Saturday.

According to South China Morning Post, its data indicates that the vaccine administered in the macaques, which uses an inactivated pathogen, induced high levels of antibodies that protect the body and provided high-level protection against the SARS-CoV-2, the virus that causes COVID-19.

The researchers administered the vaccine twice a day on day zero and day 14 of the experiment, while a placebo group was only given saline. By the end of day 24, all of the macaques are now exposed to COVID-19.

Throughout the seven-day evaluation period after immunization, they found that the placebo group maintained a high viral load. Meanwhile, swabs are taken from the vaccinated macaques, which showed a peak on viral load by the fifth day and significantly waned by the seventh day.

All animals exposed to the coronavirus were euthanized on the seventh day for pathological examination. Those macaques in the low-dose and high-dose have not shown any detectable viral load, unlike those in the placebo group.

The researchers said that the results of their study demonstrated that "both low-dose and high-dose vaccines are highly efficient in defending against SARS-CoV-2 in macaques without observed antibody-dependent enhancement of infection."

Read Also: Sinovac 99% Confident that 'CoronaVac' Will Work Effectively Against Coronavirus

Aside from the vaccine being developed under the Beijing Institute of Biological Products, its parent company, the China National Biotec Group, said that it was focusing on developing an inactivated vaccine. The company was experienced in that field, and because this type of vaccine can be safely produced, said chairman Yang Xiaoming who told the news portal Thepaper.cn.

Moreover, another subsidiary of the company, the Wuhan Institute of Biological Products, is now on its human trials on using another inactivated vaccine. They have built biosafety production facilities to produce 200 million vaccines each year.

Additionally, they are also developing vaccines that include a recombinant protein vaccine that uses genetic engineering. However, this is not the main priority for the group.

With all these vaccines underway, Shanghai vaccine expert Tao Lina warns that these vaccines could have advantages and disadvantages, and it is still early to say which type will be ready to use first.

Read More: Chinese Doctors Claim they Found New COVID-19 Cure that Can Stop Coronavirus from Spreading Even Without Vaccines

Read the rest here:
China Could Have Coronavirus Vaccine for Emergency Use As Early As This Autumn, Expert Says - Science Times

Read More...

Novavax President of R&D Dr. Gregory Glenn to Discuss the Development of COVID-19 Vaccines on Panel at 2020 BIO Digital – Yahoo Finance

Wednesday, June 10th, 2020

GAITHERSBURG, Md., June 08, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D., President of Research and Development, will join other vaccine industry leaders for a panel discussion at 2020 BIO Digital. Taking place on Tuesday, June 9 at 11:30 a.m. EDT, the panel will discuss COVID-19 vaccines. The conversation will consider the complex path from lab to clinical trials, the impact of the evolving science on candidate development and consider how collaboration will bring life-saving vaccines to the world.

Details for the panel are as follows:

About Novavax

Novavax, Inc. (NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax proprietary saponin-based Matrix-M adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit http://www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:

InvestorsNovavax, Inc. Erika Trahanir@novavax.com240-268-2022

WestwickeJohn Woolfordjohn.woolford@westwicke.com443-213-0506

MediaBrandzone/KOGS CommunicationEdna Kaplankaplan@kogspr.com617-974-8659

See the original post:
Novavax President of R&D Dr. Gregory Glenn to Discuss the Development of COVID-19 Vaccines on Panel at 2020 BIO Digital - Yahoo Finance

Read More...

Does China Have A Coronavirus Vaccine? Expert Says One Could Be Available Within Months – International Business Times

Wednesday, June 10th, 2020

KEY POINTS

Chinas top respiratory expert said Tuesday a vaccine for the coronavirus could be ready as early as autumn for emergency use, months earlier than the timeline envisioned by U.S. experts. The comments came amid a Harvard University study that found the virus began circulating in China much earlier than previously suspected.

Zhong Nanshan, former president of the Chinese Medical Association and current the editor-in-chief of the Journal of Thoracic Disease, said guidelines are being drafted to determine who will get the vaccine first and when, along with what would constitute emergency use.

Dr. Anthony Fauci, head of the U.S. National Institute of Allergy and Infectious Disease, has said 100 million doses of a vaccine could be ready by the end of the year even before trials on safety and efficacy are completed.

China has spent a reported $703 million on the development of a vaccine, with five currently undergoing testing. Several others developed elsewhere in the world also are undergoing trials, setting up a global competition akin to the space race.

The journal Cell on Saturday published a preliminary study of a vaccine developed by the Bejing Institute of Biological Products that effectively blocked infection in rhesus monkeys. Development of an effective vaccine by China likely would help deflect criticism of the countrys early handling of the outbreak.

Another vaccine developed by the Wuhan Institute of Biological Products is in the midst of human trials. Both vaccines use inactivated viruses. Research also is focused on other techniques including genetic engineering.

Zhong said without a vaccine, death tolls will continue to mount. By midmorning Tuesday, more than 407,000 people had died worldwide from COVID-19 -- more than a quarter in the United States alone.

Natural immunity needs 60- to 70% of a countrys population to be infected by the novel coronavirus, which could cause a death toll of 30 [million] to 40 million, Zhong told the South China Morning Post. The [only] solution is still mass vaccination.

He added: Large-scale vaccination will take one to two years. The new vaccine can be used in an emergency as early as this autumn or the end of the year.

China rejected findings by Harvard University that coronavirus began circulating in Wuhan as early as August by examining satellite images of hospital parking lots. Chinese Foreign Ministry spokesman Hua Chunying called the conclusions preposterous, but the researchers said the findings line up with the recent recognition that gastrointestinal symptoms are a unique feature of COVID-19 disease and may be the chief complaint of a significant proportion of presenting patients.

China has maintained the infection emerged in November but has been sharply criticized for suppressing information in the initial stages of the pandemic.

Follow this link:
Does China Have A Coronavirus Vaccine? Expert Says One Could Be Available Within Months - International Business Times

Read More...

Eight Research Projects Receive Funding from Manning Fund for COVID-19 Research – University of Virginia

Wednesday, June 10th, 2020

A recent gift of $1 million from the Manning family, strong supporters of the University of Virginia, established The Manning Fund for COVID-19 Research, designed to support the Universitys practically oriented research on COVID-19-related topics that can be acted upon quickly and have commercial potential.

More than 50 proposals were received from UVA faculty for projects related to developing COVID-19-related solutions.

The offices of the Provost and the Vice President for Research, which co-manage the fund, havefunded eight proposals that support improved antibody testing, vaccine development and improving patient outcomes.

These researchers showed they had both great ideas for conquering COVID-19, and a solid plan for how to accomplish their goals, said Melur Ram Ramasubramanian, vice president for research. We couldnt be more pleased with the projects proposed and their potential impact.

Many of our researchers have set current and pressing projects aside to redirect their energies to COVID-19, said Liz Magill, the Universitys provost. Were grateful that the Manning Fund has enabled this critical research that takes advantage of the cross-disciplinary networks UVA has nurtured over the past few years.

I want to thank the entire research team and administrationfor their acute sense of urgency and entrepreneurship to come up with these helpful solutions to the COVID crisis. They set short term goals and achieved them, said local businessman and investor Paul Manning. I am very grateful.

A rundown of the selected projects:

IgG to SARS-CoV-2 With ImmunoCAPJeffrey Wilson, School of Medicine, Asthma, Allergy & Immunology

Jeffrey Wilson and his team plan to develop a novel assay to measure antibodies to SARS-CoV-2, taking advantage of the lmmunoCAP platform and producing a quantitative readout of how much IgG is present instead of just a yes or a no, as is common in current commercial systems. This has implications in developing an understanding of the likely attachment sites of the virus and accelerating the development of effective vaccines.

A COVID-19 Killed Whole Cell Genome Reduced E. coli Fusion Peptide Subunit VaccineSteven Zeichner, School of Medicine, Pediatrics

A vaccine for COVID-19 is urgently needed to control the pandemic. Steven Zeichner and his team aim to develop a vaccine that helps the body develop antibodies directed against a specific fusion peptide found on the surface of SARS-CoV-2 virus as a component of its spike protein. The novelty of this project is the use a modified E. coli bacterial surface to display this peptide and help the body develop specific antibodies against it. When the real virus enters the body due to infection, the body can recognize this fusion peptide and neutralize the virus.

We expect the results from this project can be quickly translated into a safe, inexpensive, scalable, and effective vaccine appropriate for pandemic response globally, enabling an end to the COVID-19 pandemic not only in developed countries, but around the world, said Steven Zeichner.

Targeted Antibodies From Convalescent Plasma to Protect Against COVID-19Peter Kasson, School of Medicine, Molecular Physiology & Biomedical Engineering

Individuals vary substantially in their antibody response to COVID-19, both in amount and type of antibodies produced. Peter Kassons team aims to purify the serum from recovered patients and identify specific antibodies that are most potent against SARS-CoV-2 and to produce concentrated amounts of these target specific antibodies for the treatment of patients with increased potency.

Novel Reagents to Improve Testing for COVID-19 AntibodiesJames Zimring, School of Medicine, Pathology

The goal of James Zimring and his team is to develop novel testing reagents to eliminate the problem of cross-reactivity with common coronaviruses and develop a neutralization reagent that can be added to any serological assay and any analytic platform for antibody testing, which will eliminate signal from other non-COVID-19 antibodies and improve the accuracy of the test significantly.

Adenosine A2A Receptor Agonists in the Prevention of COVID-19-Related Lung Injury and Systemic Inflammatory ResponsesKenneth Brayman, School of Medicine, Surgery & Molecular Physiology, Infectious Diseases

The main cause of death in COVID-19 is acute respiratory distress syndrome, which is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. Kenneth Brayman and his team aim to test the use of Adenosine A2AR agonists to reduce the mortality associated with COVID-19. This immunotherapy is expected to be used preemptively, in the asymptomatic phase to prevent onset of COVID-19 or in the symptomatic phase, to reverse progression.

Isolation and Identification of Novel T-cell Receptors Responsive to SARS-CoV-2 for the Genetic Engineering of Third-Party T-cells for Off-the-Shelf Therapeutic UseDaniel Lee, School of Medicine, Hematology/Oncology, Pediatric

Daniel Lee and his team plan to study the T-cell-based immune response from patients who have been infected SARS-CoV-2 to identify viral specific T-cell receptors with the future goal of genetically engineering third-party, allogeneic T-cells with the responsive T-cell receptor, thereby producing an off-the-shelf cellular therapeutic bank for the treatment of subsequent infected patients experiencing severe symptoms. This cell therapy would be especially beneficial for immunocompromised patients infected with COVID-19.

Mass Cytometry to Identify Biomarkers for COVID-19 Severity and Response to JAK InhibitionHema Kothari, School of Medicine, Medicine & Cardiovascular Medicine

Cytokine storm in patients has been linked to COVID-19 disease severity. Hema Kotharis team aims to develop a customized diagnostic biomarker assay for early identification of those at risk of a cytokine storm and improve patient outcomes by taking timely action to block cytokines.

COVID-19: Big Data and Analytics for Early Detection of Cardiorespiratory DeteriorationRandall Moorman, School of Medicine, Medicine, Biomedical Engineering and Molecular Physiology and Biological Physics

Randall Moormans team at UVA Center for Advanced Medical Analytics plans to apply artificial intelligence and big data techniques to the problem of acute and unsuspected clinical deterioration of SARS-CoV-2-infected patients, with the goal to provide continuous risk estimation of imminent deterioration using mathematical analysis of readily available clinical and monitoring data.

Originally posted here:
Eight Research Projects Receive Funding from Manning Fund for COVID-19 Research - University of Virginia

Read More...

Page 14«..10..13141516..2030..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick